{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-015804","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.297527+00:00","generated_at":"2026-06-15T21:48:56.592374+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Avalo Therapeutics enters $9M at-the-market equity offering with Oppenheimer","bullets":["Sales Agreement with Oppenheimer & Co. for up to $9,032,567 of common stock.","Commission of 3.0% of gross proceeds; ATM offering under Rule 415.","Shares sold under existing S-3 registration statement effective May 2, 2023.","Company may suspend or terminate offering; no obligation to sell shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-015804","json":"https://secwatch.observer/filing/0001628280-23-015804.json","markdown":"https://secwatch.observer/filing/0001628280-23-015804.md","text":"https://secwatch.observer/filing/0001628280-23-015804.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023015804/0001628280-23-015804-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023015804/avtx-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:48:56.592374+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e01e9c49e95d1070b191eb139e346f89df35c3fd","claim":"Avalo Therapeutics, Inc. entered into Sales Agreement with Oppenheimer & Co. Inc. valued at up to $9,032,567 (effective 2023-05-04).","evidence_excerpt":"On May 4, 2023, Avalo Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with Oppenheimer & Co. Inc. (“Oppenheimer”), as sales agent, pursuant to which the Company may offer and sell, from time to time through Oppenheimer, shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering price of up to $9,032,567 (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023015804/0001628280-23-015804-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Oppenheimer & Co. Inc."},{"label":"Value","value":"up to $9,032,567"},{"label":"Effective","value":"2023-05-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}